Abstract
Follow-up after prostate cancer radiotherapy aims at detecting local or metastatic relapse, as well as long-term toxicity, requiring adapted treatments. Several scientific societies have published guidelines including clinical, biological and imaging recommendations. More data suggest a role for aggressive salvage therapy in case of local failure following radiotherapy. An adequate follow-up is required for the sake of patients' safety, i.e. to a posteriori validate dose constraints and radiation technique in each radiotherapy department.
Copyright © 2011 Société française de radiothérapie oncologique (SFRO). Published by Elsevier SAS. All rights reserved.
MeSH terms
-
Adenocarcinoma / blood
-
Adenocarcinoma / radiotherapy*
-
Adenocarcinoma / surgery
-
Aftercare*
-
Androgens
-
Brachytherapy / adverse effects
-
Combined Modality Therapy
-
Erectile Dysfunction / etiology
-
Follow-Up Studies
-
Hormone Antagonists / therapeutic use
-
Humans
-
Intestines / radiation effects
-
Male
-
Neoplasms, Hormone-Dependent / drug therapy
-
Neoplasms, Hormone-Dependent / radiotherapy
-
Neoplasms, Hormone-Dependent / surgery
-
Neoplasms, Radiation-Induced / diagnosis
-
Neoplasms, Radiation-Induced / etiology
-
Neoplasms, Second Primary / diagnosis
-
Neoplasms, Second Primary / etiology
-
Orchiectomy
-
Organs at Risk
-
Palpation
-
Population Surveillance*
-
Prostate-Specific Antigen / blood
-
Prostatic Neoplasms / blood
-
Prostatic Neoplasms / radiotherapy*
-
Prostatic Neoplasms / surgery
-
Radiation Injuries / etiology
-
Radiation Injuries / therapy
-
Radiotherapy / adverse effects
-
Recurrence
-
Salvage Therapy
-
Urinary Tract / radiation effects
Substances
-
Androgens
-
Hormone Antagonists
-
Prostate-Specific Antigen